Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corporation (Nasdaq: CTSO) on August 13, 2024. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a new Chief Financial Officer (CFO).
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Executive Transition: Kathleen P. Bloch retired as CFO effective August 13, 2024, and transitioned to a consulting role.
- New Appointment: Peter J. Mariani was appointed as the new CFO, effective August 14, 2024.
- Compensation Structure: Mr. Mariani's annual base salary is set at $425,000 with a potential cash bonus of up to 45% of base salary.
Outlook, Risks, and Unusual Items
Employment Terms: Mr. Mariani's employment agreement has an initial term ending December 31, 2025, with automatic one-year renewals unless 60 days' notice is given. He is eligible for annual equity awards starting in 2025.
Inducement Awards: Upon the effective date, Mr. Mariani received the following inducement awards:
- 80,000 Nonqualified Stock Options (Time-Based Vesting)
- 215,000 Nonqualified Stock Options (Performance-Based Vesting)
- 65,000 Restricted Stock Units (Time-Based Vesting)
- 175,000 Change in Control Restricted Stock Units
- 110,000 Signing Restricted Stock Units
Consulting Arrangement: Ms. Bloch will serve as a consultant until December 31, 2025, at an hourly rate of $335 to assist with the transition. She retains vesting rights for previously awarded RSUs and is eligible for COBRA health plan reimbursement for 12 months.
Investor Verification Checklist
- Verify the vesting schedules and performance milestones for Mr. Mariani's 215,000 performance-based stock options.
- Review the full Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control" termination benefits.
- Confirm the total dilution impact of the 645,000 total inducement equity units granted to Mr. Mariani.
- Monitor the transition progress between the outgoing and incoming CFOs as detailed in the Consulting Agreement (Exhibit 10.5).